^
Association details:
Biomarker:KDR overexpression
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer

Published date:
10/05/2023
Excerpt:
CONTRADICTING EVIDENCE: According to the receiver operating characteristics and Kaplan-Meier curve analyses, patients with high c-MET, EGFR, and VEGFR2 expression at baseline had significantly shorter PFS than those with low expression.
Secondary therapy:
Chemotherapy
DOI:
10.3389/fimmu.2023.1086479
Evidence Level:
Sensitive: C3 – Early Trials
Title:

EP08.01-054 - ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer

Published date:
07/12/2022
Excerpt:
During treatment,the expression level of VEGFR2 increased in beneficial patients and decreased in non-beneficial patients, which can be used as a marker for monitoring therapeutic efficacy…The combination of ICIs combined with single-agent chemotherapy shows safety,efficacy, and tolerable adverse events in two or more lines treatment for advanced non-small cell lung cancer.
Secondary therapy:
Chemotherapy